Effectiveness, Safety and Therapeutic Adherenceof Weekly Subcutaneous Semaglutide for WeightManagement in Real Practice: An Observational Study
2021
In a retrospective study, 367 patients (mean age 50.25 years, 78.36% female, mean baseline body
mass index 32.39 kg/m2) were followed for 10.7 months (median) after initiation of semaglutide. Up to 24.25% of patients were
previously on GLP-1 analogue therapy (mostly liraglutide) and 36.26% used background oral medication for weight loss.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI